Protocol Ledger

NCT06540963 · Phase II · RECRUITING

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Interventional Phase II clinical trial protocol NCT06540963 sponsored by Giselle Sholler in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-06 Enrollment: 98 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06540963
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)98 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06540963
Protocol FieldVerified Registry Value
NCT IdentifierNCT06540963
Consolidated Lead SponsorGiselle Sholler
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment98 participants (ESTIMATED)
Registered Start Date2024-12-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI